Oncotarget is a free open-access medical journal that gives researchers access to information in the field of oncology. The reason Oncotarget has endeavored to make this information easily accessible is to have a greater impact on research.
How Does This Affect the Medical Community?
One of the caveats of research, especially in the world of oncology, is that over time it can foster a sense of competition between researchers. There are researchers who want to make that next big ‘breakthrough’ to help combat the disease. While this is a worthy cause to pursue, there is the downside that it can also hinder research from moving forward. Creating a gap between researchers who may have otherwise been working together to work towards a common goal.
Oncotarget bridges this gap by staying dedicated to their mission to make scientific results widely and rapidly available. Their multidisciplinary traditional journal is free to access so researchers can go over the content. The published papers come out in weekly issues online, but each issue or paper can be printed for a special demand. Visit his profile on Google Scholar.
The other benefit of oncotarget is how they seek to maximize the effect research has based on the insightful review. There are exceptional discoveries made in the world of oncology, but researchers may not hear of it because they’re so focused on their own work. Sharing this discovery helps to bridge the border between specialties and even link different fields of study. Information can be shared freely between specialists and help to lead them to make more breakthroughs in their own field.
Oncotarget seeks to foster these applications of basic and clinical science in the world of oncology. Aiding researchers with new ways to fight the disease and to maximize the effect of the research they do daily.
Under the leadership of several prominent scientists, the journal has helped researchers to contribute to the continued progress of science. The goal being to have life without disease worldwide.
Read more: http://www.scimagojr.com/journalsearch.php?q=19900191708&tip=sid
Mikhail Blagosklonny is not only dedicated to his craft within cancer departments of medical schools on ImpactJournals.com, but is also interested in the mechanism for aging and learning how aging can affect cancerous cells within the body. Mikhail Blagosklonny has created many interesting research topics and hopes to continue his research and to pass on his findings to interested students in the future. Mikhail Blagosklonny is specifically a scientist who has taken an interest in studying cancer and aging in order to help cancerous patients have an improved treatment that is not only more effective, but is also more comfortable to their mind as well as to their body. Mikhail Blagosklonny is currently a professor who continues to conduct research and has become an influential individual within oncology departments with his numerous discoveries and research papers that have influenced the field of medicine.
Mikhail Blagosklonny has not only received his MD in internal medicine, but has also received his PhD in experimental medicine and even in cardiology. His experience in academics makes him a knowledgeable and influential individual who will have a well respected name in years to come. Mikhail Blagosklonny is a professor of medicine and has had the goal of conducting research with his students in order to influence them to continue his research in the study. Mikhail Blagosklonny has always loved helping others and hopes that his students will share the same passion that he has within the medical fields of both cancer as well as within aging.
The main goal of Mikhail Blagosklonny is to conduct research on tandfonline.com in order to find a way to treat cancer that will specifically target the dangerous cancer cells within the body without destroying the normal cells within the system which can prevent full recovery of the body even after the cancer has been cured. As a professor, Mikhail Blagosklonny has been able to inspire not only his peers, but also his employees to learn more about his findings.